Using their trading system, Zack's experts give you their prediction for GILD in free RPT. Should you pass or buy Gilead? Zacks experts tell all in a new free Special Report.
- Chipmaker Set to Soar Now
Best 2024 Semiconductor Stock?
One Chipmaker Worth Buying Now
- The Top IPO Stock Plays
Could IPOs be the Key to Success?
Investing in IPOs is on the Rise
- Top Clean Energy Stocks
How to profit from surging demand.
Free report reveals 5 hot stocks.
- Top Hydrogen Stock Plays
5 Hydrogen stocks to buy right now
New report names 5 wealth-builders
- Anti-Gold Investor Guide
Investments to buy instead of gold
Free guide to protect your wealth
- 3 Hottest Software Stocks
Top plays from a surging industry.
Free report names must-buy stocks.
- Chipmaker Set to Soar Now
Suchergebnisse
Suchergebnisse:
Vor 3 Tagen · News zur GILEAD SCIENCES AKTIE und aktueller Realtime-Aktienkurs AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug.
- (25)
12. Sept. 2024 · – 99.9% of Participants Did Not Acquire HIV Infection in the Lenacapavir Group, with 2 Incident Cases Among 2,180 Participants – – PURPOSE 2 Trial Results for Cisgender Men and Gender-Diverse People Add to the Body of Evidence for the Investigational Use of Lenacapavir for HIV Prevention –
12. Feb. 2024 · FOSTER CITY, Calif. & NEWARK, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
22. Jan. 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
12. Sept. 2024 · Gilead Sciences News: auf dieser Seite finden Sie alle Gilead Sciences News und Nachrichten zur Gilead Sciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Gilead...
20. Juni 2024 · Gilead announced 100% efficacy and superiority of lenacapavir over oral Truvada and background HIV incidence in cisgender women. The trial is part of the PURPOSE program, the most comprehensive and diverse HIV prevention trial program ever conducted.
3. Feb. 2023 · Feb 3 (Reuters) - Gilead Sciences (GILD.O) said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option...
